TLR3 and breast cancer: Furthermore, Di et al. proved that administration of the toll-like receptor 3 (TLR3) ligand polyinosinic-polycytidylic acid (poly I:C) can increase EGFRvIII-specific CAR-T cell efficacy in immune competent mice bearing colon and breast cancers by enhancing specific lysis of cancer cells and cytokine release upon antigen stimulation.